世界の組換えペプチド市場予測 2021年-2026年

【英語タイトル】Global Recombinant Peptide Market Growth 2021-2026

LP Informationが出版した調査資料(LPI21MY9566)・商品コード:LPI21MY9566
・発行会社(調査会社):LP Information
・発行日:2021年5月(※2024年版があります。お問い合わせください)
・ページ数:132
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後2-3営業日)
・調査対象地域:グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
・産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,660 ⇒換算¥541,680見積依頼/購入/質問フォーム
Multi User(20名様閲覧用)USD5,490 ⇒換算¥812,520見積依頼/購入/質問フォーム
Corporate User(閲覧人数制限なし)USD7,320 ⇒換算¥1,083,360見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
LPインフォメーション社の「組換えペプチドの世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、グルカゴン、カルシトニン、その他など、用途別には、腫瘍、血液疾患、感染症、自己免疫疾患、その他などにセグメント区分してまとめました。組換えペプチドのグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。
・組換えペプチドの世界市場概要(サマリー)
・組換えペプチドの企業別販売量・売上
・組換えペプチドの企業別市場シェア
・組換えペプチドの世界市場規模 2016年-2021年:種類別(グルカゴン、カルシトニン、その他)
・組換えペプチドの世界市場規模 2016年-2021年:用途別(腫瘍、血液疾患、感染症、自己免疫疾患、その他)
・組換えペプチドの南北アメリカ市場規模(アメリカ、カナダ、メキシコなど)
・組換えペプチドのアジア市場規模(日本、中国、韓国、インド、東南アジアなど)
・組換えペプチドのヨーロッパ市場規模(ドイツ、フランス、イギリス、イタリア、ロシアなど)
・組換えペプチドの中東・アフリカ市場(エジプト、南アフリカ、トルコ、GCC諸国など)
・組換えペプチド市場の成長要因・課題・動向
・組換えペプチドの世界市場予測 2021年-2026年
・組換えペプチドの南北アメリカ市場予測(アメリカ、カナダ、メキシコなど)
・組換えペプチドのアジア市場予測(日本、中国、韓国、インド、東南アジアなど)
・組換えペプチドのヨーロッパ市場予測(ドイツ、フランス、イギリス、イタリア、ロシアなど)
・組換えペプチドの中東・アフリカ市場予測(エジプト、南アフリカ、トルコ、GCC諸国など)
・組換えペプチドの世界市場予測:種類別(グルカゴン、カルシトニン、その他)
・組換えペプチドの世界市場予測:用途別(腫瘍、血液疾患、感染症、自己免疫疾患、その他)
・主要企業分析
【レポートの概要】

According to this latest study, the 2020 growth of Recombinant Peptide will have significant change from previous year. By the most conservative estimates of global Recombinant Peptide market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. Over the next five years the Recombinant Peptide market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2025.

This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Peptide market by product type, application, key manufacturers and key regions and countries.

Segmentation by type: breakdown data from 2016 to 2021, in Section 2.3; and forecast to 2026 in section 11.7.
Glucagon
Calcitonin
Other

Segmentation by application: breakdown data from 2016 to 2021, in Section 2.4; and forecast to 2026 in section 11.8.
Oncology
Blood Disorders
Infectious Diseases
Autoimmune Diseases
Other

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in Chapter 3.
Sandoz Pharma
Stada Arzneimittel
Amgen
Hospira
Actavis
Cipla Ltd.
Wockhardt Ltd.
Biocon Ltd.

【レポートの目次】

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Recombinant Peptide Consumption 2016-2026
2.1.2 Recombinant Peptide Consumption CAGR by Region
2.2 Recombinant Peptide Segment by Type
2.2.1 Glucagon
2.2.2 Calcitonin
2.2.3 Other
2.3 Recombinant Peptide Sales by Type
2.3.1 Global Recombinant Peptide Sales Market Share by Type (2016-2021)
2.3.2 Global Recombinant Peptide Revenue and Market Share by Type (2016-2021)
2.3.3 Global Recombinant Peptide Sale Price by Type (2016-2021)
2.4 Recombinant Peptide Segment by Application
2.4.1 Oncology
2.4.2 Blood Disorders
2.4.3 Infectious Diseases
2.4.4 Autoimmune Diseases
2.4.5 Other
2.5 Recombinant Peptide Sales by Application
2.5.1 Global Recombinant Peptide Sale Market Share by Application (2016-2021)
2.5.2 Global Recombinant Peptide Revenue and Market Share by Application (2016-2021)
2.5.3 Global Recombinant Peptide Sale Price by Application (2016-2021)

3 Global Recombinant Peptide by Company
3.1 Global Recombinant Peptide Sales Market Share by Company
3.1.1 Global Recombinant Peptide Sales by Company (2019-2021)
3.1.2 Global Recombinant Peptide Sales Market Share by Company (2019-2021)
3.2 Global Recombinant Peptide Revenue Market Share by Company
3.2.1 Global Recombinant Peptide Revenue by Company (2019-2021)
3.2.2 Global Recombinant Peptide Revenue Market Share by Company (2019-2021)
3.3 Global Recombinant Peptide Sale Price by Company
3.4 Global Manufacturers Recombinant Peptide Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Recombinant Peptide Product Location Distribution
3.4.2 Players Recombinant Peptide Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 Recombinant Peptide by Region
4.1 Global Recombinant Peptide by Region
4.1.1 Global Recombinant Peptide Sales by Region
4.1.2 Global Recombinant Peptide Revenue by Region
4.2 Americas Recombinant Peptide Sales Growth
4.3 APAC Recombinant Peptide Sales Growth
4.4 Europe Recombinant Peptide Sales Growth
4.5 Middle East & Africa Recombinant Peptide Sales Growth

5 Americas
5.1 Americas Recombinant Peptide Sales by Country
5.1.1 Americas Recombinant Peptide Sales by Country (2016-2021)
5.1.2 Americas Recombinant Peptide Revenue by Country (2016-2021)
5.2 Americas Recombinant Peptide Sales by Type
5.3 Americas Recombinant Peptide Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC
6.1 APAC Recombinant Peptide Sales by Region
6.1.1 APAC Recombinant Peptide Sales by Region (2016-2021)
6.1.2 APAC Recombinant Peptide Revenue by Region (2016-2021)
6.2 APAC Recombinant Peptide Sales by Type
6.3 APAC Recombinant Peptide Sales by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 Europe
7.1 Europe Recombinant Peptide by Country
7.1.1 Europe Recombinant Peptide Sales by Country (2016-2021)
7.1.2 Europe Recombinant Peptide Revenue by Country (2016-2021)
7.2 Europe Recombinant Peptide Sales by Type
7.3 Europe Recombinant Peptide Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 Middle East & Africa
8.1 Middle East & Africa Recombinant Peptide by Country
8.1.1 Middle East & Africa Recombinant Peptide Sales by Country (2016-2021)
8.1.2 Middle East & Africa Recombinant Peptide Revenue by Country (2016-2021)
8.2 Middle East & Africa Recombinant Peptide Sales by Type
8.3 Middle East & Africa Recombinant Peptide Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Country

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Recombinant Peptide Distributors
10.3 Recombinant Peptide Customer

11 Global Recombinant Peptide Market Forecast
11.1 Global Recombinant Peptide Forecast by Region
11.1.1 Global Recombinant Peptide Forecast by Regions (2021-2026)
11.2.2 Global Recombinant Peptide Revenue Forecast by Regions (2021-2026)
11.2 Americas Forecast by Countries
11.3 APAC Forecast by Region
11.4 Europe Forecast by Countries
11.5 Middle East & Africa Forecast by Countries
11.6 Global Recombinant Peptide Forecast by Type
11.7 Global Recombinant Peptide Forecast by Application

12 Key Players Analysis
12.1 Sandoz Pharma
12.1.1 Sandoz Pharma Sandoz Pharma Company Information
12.1.2 Sandoz Pharma Recombinant Peptide Product Offered
12.1.3 Sandoz Pharma Recombinant Peptide Sales, Revenue, Price and Gross Margin (2019-2021)
12.1.4 Sandoz Pharma Main Business Overview
12.1.5 Sandoz Pharma Latest Developments
12.2 Stada Arzneimittel
12.2.1 Stada Arzneimittel Company Information
12.2.2 Stada Arzneimittel Recombinant Peptide Product Offered
12.2.3 Stada Arzneimittel Recombinant Peptide Sales, Revenue, Price and Gross Margin (2019-2021)
12.2.4 Stada Arzneimittel Main Business Overview
12.2.5 Stada Arzneimittel Latest Developments
12.3 Amgen
12.3.1 Amgen Company Information
12.3.2 Amgen Recombinant Peptide Product Offered
12.3.3 Amgen Recombinant Peptide Sales, Revenue, Price and Gross Margin (2019-2021)
12.3.4 Amgen Main Business Overview
12.3.5 Amgen Latest Developments
12.4 Hospira
12.4.1 Hospira Company Information
12.4.2 Hospira Recombinant Peptide Product Offered
12.4.3 Hospira Recombinant Peptide Sales, Revenue, Price and Gross Margin (2019-2021)
12.4.4 Hospira Main Business Overview
12.4.5 Hospira Latest Developments
12.5 Actavis
12.5.1 Actavis Company Information
12.5.2 Actavis Recombinant Peptide Product Offered
12.5.3 Actavis Recombinant Peptide Sales, Revenue, Price and Gross Margin (2019-2021)
12.5.4 Actavis Main Business Overview
12.5.5 Actavis Latest Developments
12.6 Cipla Ltd.
12.6.1 Cipla Ltd. Company Information
12.6.2 Cipla Ltd. Recombinant Peptide Product Offered
12.6.3 Cipla Ltd. Recombinant Peptide Sales, Revenue, Price and Gross Margin (2019-2021)
12.6.4 Cipla Ltd. Main Business Overview
12.6.5 Cipla Ltd. Latest Developments
12.7 Wockhardt Ltd.
12.7.1 Wockhardt Ltd. Company Information
12.7.2 Wockhardt Ltd. Recombinant Peptide Product Offered
12.7.3 Wockhardt Ltd. Recombinant Peptide Sales, Revenue, Price and Gross Margin (2019-2021)
12.7.4 Wockhardt Ltd. Main Business Overview
12.7.5 Wockhardt Ltd. Latest Developments
12.8 Biocon Ltd.
12.8.1 Biocon Ltd. Company Information
12.8.2 Biocon Ltd. Recombinant Peptide Product Offered
12.8.3 Biocon Ltd. Recombinant Peptide Sales, Revenue, Price and Gross Margin (2019-2021)
12.8.4 Biocon Ltd. Main Business Overview
12.8.5 Biocon Ltd. Latest Developments

13 Research Findings and Conclusion

List of Tables
Table 1. Recombinant Peptide Consumption CAGR by Region (2020-2026) & ($ Millions)
Table 2. Major Players of Glucagon
Table 3. Major Players of Calcitonin
Table 4. Major Players of Other
Table 5. Global Recombinant Peptide Sales by Type (2016-2021) & (K Units)
Table 6. Global Recombinant Peptide Sales Market Share by Type (2016-2021)
Table 7. Global Recombinant Peptide Revenue by Type (2016-2021) & ($ million)
Table 8. Global Recombinant Peptide Revenue Market Share by Type (2016-2021)
Table 9. Global Recombinant Peptide Sale Price by Type (2016-2021)
Table 10. Global Recombinant Peptide Sales by Application (2016-2021) & (K Units)
Table 11. Global Recombinant Peptide Sales Market Share by Application (2016-2021)
Table 12. Global Recombinant Peptide Value by Application (2016-2021)
Table 13. Global Recombinant Peptide Revenue Market Share by Application (2016-2021)
Table 14. Global Recombinant Peptide Sale Price by Application (2016-2021)
Table 15. Global Recombinant Peptide Sales by Company (2019-2021) & (K Units)
Table 16. Global Recombinant Peptide Sales Market Share by Company (2019-2021)
Table 17. Global Recombinant Peptide Revenue by Company (2019-2021) ($ Millions)
Table 18. Global Recombinant Peptide Revenue Market Share by Company (2019-2021)
Table 19. Global Recombinant Peptide Sale Price by Company (2019-2021)
Table 20. Key Manufacturers Recombinant Peptide Producing Area Distribution and Sales Area
Table 21. Players Recombinant Peptide Products Offered
Table 22. Recombinant Peptide Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Recombinant Peptide Sales by Region (2016-2021) (K Units)
Table 26. Global Recombinant Peptide Sales Market Share by Region (2016-2021)
Table 27. Global Recombinant Peptide Revenue by Region (2016-2021) & ($ Millions)
Table 28. Global Recombinant Peptide Revenue Market Share by Region (2016-2021)
Table 29. Americas Recombinant Peptide Sales by Country (2016-2021) & (K Units)
Table 30. Americas Recombinant Peptide Sales Market Share by Country (2016-2021)
Table 31. Americas Recombinant Peptide Revenue by Country (2016-2021) & ($ Millions)
Table 32. Americas Recombinant Peptide Revenue Market Share by Country (2016-2021)
Table 33. Americas Recombinant Peptide Sales by Type (2016-2021) & (K Units)
Table 34. Americas Recombinant Peptide Sales Market Share by Type (2016-2021)
Table 35. Americas Recombinant Peptide Sales by Application (2016-2021) & (K Units)
Table 36. Americas Recombinant Peptide Sales Market Share by Application (2016-2021)
Table 37. APAC Recombinant Peptide Sales by Region (2016-2021) & (K Units)
Table 38. APAC Recombinant Peptide Sales Market Share by Region (2016-2021)
Table 39. APAC Recombinant Peptide Revenue by Region (2016-2021) & ($ Millions)
Table 40. APAC Recombinant Peptide Revenue Market Share by Region (2016-2021)
Table 41. APAC Recombinant Peptide Sales by Type (2016-2021) & (K Units)
Table 42. APAC Recombinant Peptide Sales Market Share by Type (2016-2021)
Table 43. APAC Recombinant Peptide Sales by Application (2016-2021) & (K Units)
Table 44. APAC Recombinant Peptide Sales Market Share by Application (2016-2021)
Table 45. Europe Recombinant Peptide Sales by Country (2016-2021) & (K Units)
Table 46. Europe Recombinant Peptide Sales Market Share by Country (2016-2021)
Table 47. Europe Recombinant Peptide Revenue by Country (2016-2021) & ($ Millions)
Table 48. Europe Recombinant Peptide Revenue Market Share by Country (2016-2021)
Table 49. Europe Recombinant Peptide Sales by Type (2016-2021) & (K Units)
Table 50. Europe Recombinant Peptide Sales Market Share by Type (2016-2021)
Table 51. Europe Recombinant Peptide Sales by Application (2016-2021) & (K Units)
Table 52. Europe Recombinant Peptide Sales Market Share by Application (2016-2021)
Table 53. Middle East & Africa Recombinant Peptide Sales by Country (2016-2021) & (K Units)
Table 54. Middle East & Africa Recombinant Peptide Sales Market Share by Country (2016-2021)
Table 55. Middle East & Africa Recombinant Peptide Revenue by Country (2016-2021) & ($ Millions)
Table 56. Middle East & Africa Recombinant Peptide Revenue Market Share by Country (2016-2021)
Table 57. Middle East & Africa Recombinant Peptide Sales by Type (2016-2021) & (K Units)
Table 58. Middle East & Africa Recombinant Peptide Sales Market Share by Type (2016-2021)
Table 59. Middle East & Africa Recombinant Peptide Sales by Application (2016-2021) & (K Units)
Table 60. Middle East & Africa Recombinant Peptide Sales Market Share by Application (2016-2021)
Table 61. Global Recombinant Peptide Sales Forecast by Type (2021-2026) & (K Units)
Table 62. Global Recombinant Peptide Sales Market Share Forecast by Type (2021-2026)
Table 63. Global Recombinant Peptide Revenue Forecast by Type (2021-2026) & ($ Millions)
Table 64. Global Recombinant Peptide Revenue Market Share Forecast by Type (2021-2026)
Table 65. Global Recombinant Peptide Sales Forecast by Application (2021-2026) & (K Units)
Table 66. Global Recombinant Peptide Sales Market Share Forecast by Application (2021-2026)
Table 67. Global Recombinant Peptide Revenue Forecast by Application (2021-2026) & ($ Millions)
Table 68. Global Recombinant Peptide Revenue Market Share Forecast by Application (2021-2026)
Table 69. Sandoz Pharma Basic Information, Recombinant Peptide Manufacturing Base, Sales Area and Its Competitors
Table 70. Sandoz Pharma Recombinant Peptide Product Offered
Table 71. Sandoz Pharma Recombinant Peptide Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 72. Sandoz Pharma Main Business
Table 73. Sandoz Pharma Latest Developments
Table 74. Stada Arzneimittel Basic Information, Recombinant Peptide Manufacturing Base, Sales Area and Its Competitors
Table 75. Stada Arzneimittel Recombinant Peptide Product Offered
Table 76. Stada Arzneimittel Recombinant Peptide Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 77. Stada Arzneimittel Main Business
Table 78. Stada Arzneimittel Latest Developments
Table 79. Amgen Basic Information, Recombinant Peptide Manufacturing Base, Sales Area and Its Competitors
Table 80. Amgen Recombinant Peptide Product Offered
Table 81. Amgen Recombinant Peptide Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 82. Amgen Main Business
Table 83. Amgen Latest Developments
Table 84. Hospira Basic Information, Recombinant Peptide Manufacturing Base, Sales Area and Its Competitors
Table 85. Hospira Recombinant Peptide Product Offered
Table 86. Hospira Recombinant Peptide Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 87. Hospira Main Business
Table 88. Hospira Latest Developments
Table 89. Actavis Basic Information, Recombinant Peptide Manufacturing Base, Sales Area and Its Competitors
Table 90. Actavis Recombinant Peptide Product Offered
Table 91. Actavis Recombinant Peptide Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 92. Actavis Main Business
Table 93. Actavis Latest Developments
Table 94. Cipla Ltd. Basic Information, Recombinant Peptide Manufacturing Base, Sales Area and Its Competitors
Table 95. Cipla Ltd. Recombinant Peptide Product Offered
Table 96. Cipla Ltd. Recombinant Peptide Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 97. Cipla Ltd. Main Business
Table 98. Cipla Ltd. Latest Developments
Table 99. Wockhardt Ltd. Basic Information, Recombinant Peptide Manufacturing Base, Sales Area and Its Competitors
Table 100. Wockhardt Ltd. Recombinant Peptide Product Offered
Table 101. Wockhardt Ltd. Recombinant Peptide Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 102. Wockhardt Ltd. Main Business
Table 103. Wockhardt Ltd. Latest Developments
Table 104. Biocon Ltd. Basic Information, Recombinant Peptide Manufacturing Base, Sales Area and Its Competitors
Table 105. Biocon Ltd. Recombinant Peptide Product Offered
Table 106. Biocon Ltd. Recombinant Peptide Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)
Table 107. Biocon Ltd. Main Business
Table 108. Biocon Ltd. Latest Developments
List of Figures
Figure 1. Picture of Recombinant Peptide
Figure 2. Recombinant Peptide Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Recombinant Peptide Sales Growth Rate 2016-2026 (K Units)
Figure 7. Global Recombinant Peptide Revenue Growth Rate 2016-2026 ($ Millions)
Figure 8. Recombinant Peptide Sales by Region (2021 & 2026) & ($ millions)
Figure 9. Product Picture of Glucagon
Figure 10. Product Picture of Calcitonin
Figure 11. Product Picture of Other
Figure 12. Global Recombinant Peptide Sales Market Share by Type in 2020
Figure 13. Global Recombinant Peptide Revenue Market Share by Type (2016-2021)
Figure 14. Recombinant Peptide Consumed in Oncology
Figure 15. Global Recombinant Peptide Market: Oncology (2016-2021) & (K Units)
Figure 16. Recombinant Peptide Consumed in Blood Disorders
Figure 17. Global Recombinant Peptide Market: Blood Disorders (2016-2021) & (K Units)
Figure 18. Recombinant Peptide Consumed in Infectious Diseases
Figure 19. Global Recombinant Peptide Market: Infectious Diseases (2016-2021) & (K Units)
Figure 20. Recombinant Peptide Consumed in Autoimmune Diseases
Figure 21. Global Recombinant Peptide Market: Autoimmune Diseases (2016-2021) & (K Units)
Figure 22. Recombinant Peptide Consumed in Other
Figure 23. Global Recombinant Peptide Market: Other (2016-2021) & (K Units)
Figure 24. Global Recombinant Peptide Sales Market Share by Application (2016-2021)
Figure 25. Global Recombinant Peptide Revenue Market Share by Application in 2020
Figure 26. Global Recombinant Peptide Revenue Market by Company in 2020 ($ Million)
Figure 27. Global Recombinant Peptide Revenue Market Share by Company in 2020
Figure 28. Global Recombinant Peptide Sales Market Share by Regions (2016-2021)
Figure 29. Global Recombinant Peptide Revenue Market Share by Region in 2020
Figure 30. Americas Recombinant Peptide Sales 2016-2021 (K Units)
Figure 31. Americas Recombinant Peptide Revenue 2016-2021 ($ Millions)
Figure 32. APAC Recombinant Peptide Sales 2016-2021 (K Units)
Figure 33. APAC Recombinant Peptide Revenue 2016-2021 ($ Millions)
Figure 34. Europe Recombinant Peptide Sales 2016-2021 (K Units)
Figure 35. Europe Recombinant Peptide Revenue 2016-2021 ($ Millions)
Figure 36. Middle East & Africa Recombinant Peptide Sales 2016-2021 (K Units)
Figure 37. Middle East & Africa Recombinant Peptide Revenue 2016-2021 ($ Millions)
Figure 38. Americas Recombinant Peptide Sales Market Share by Country in 2020
Figure 39. Americas Recombinant Peptide Revenue Market Share by Country in 2020
Figure 40. Americas Recombinant Peptide Sales Market Share by Type in 2020
Figure 41. Americas Recombinant Peptide Sales Market Share by Application in 2020
Figure 42. United States Recombinant Peptide Revenue Growth 2016-2021 ($ Millions)
Figure 43. Canada Recombinant Peptide Revenue Growth 2016-2021 ($ Millions)
Figure 44. Mexico Recombinant Peptide Revenue Growth 2016-2021 ($ Millions)
Figure 45. Brazil Recombinant Peptide Revenue Growth 2016-2021 ($ Millions)
Figure 46. APAC Recombinant Peptide Sales Market Share by Region in 2020
Figure 47. APAC Recombinant Peptide Revenue Market Share by Regions in 2020
Figure 48. APAC Recombinant Peptide Sales Market Share by Type in 2020
Figure 49. APAC Recombinant Peptide Sales Market Share by Application in 2020
Figure 50. China Recombinant Peptide Revenue Growth 2016-2021 ($ Millions)
Figure 51. Japan Recombinant Peptide Revenue Growth 2016-2021 ($ Millions)
Figure 52. Korea Recombinant Peptide Revenue Growth 2016-2021 ($ Millions)
Figure 53. Southeast Asia Recombinant Peptide Revenue Growth 2016-2021 ($ Millions)
Figure 54. India Recombinant Peptide Revenue Growth 2016-2021 ($ Millions)
Figure 55. Australia Recombinant Peptide Revenue Growth 2016-2021 ($ Millions)
Figure 56. Europe Recombinant Peptide Sales Market Share by Country in 2020
Figure 57. Europe Recombinant Peptide Revenue Market Share by Country in 2020
Figure 58. Europe Recombinant Peptide Sales Market Share by Type in 2020
Figure 59. Europe Recombinant Peptide Sales Market Share by Application in 2020
Figure 60. Germany Recombinant Peptide Revenue Growth 2016-2021 ($ Millions)
Figure 61. France Recombinant Peptide Revenue Growth 2016-2021 ($ Millions)
Figure 62. UK Recombinant Peptide Revenue Growth 2016-2021 ($ Millions)
Figure 63. Italy Recombinant Peptide Revenue Growth 2016-2021 ($ Millions)
Figure 64. Russia Recombinant Peptide Revenue Growth 2016-2021 ($ Millions)
Figure 65. Middle East & Africa Recombinant Peptide Sales Market Share by Country in 2020
Figure 66. Middle East & Africa Recombinant Peptide Revenue Market Share by Country in 2020
Figure 67. Middle East & Africa Recombinant Peptide Sales Market Share by Type in 2020
Figure 68. Middle East & Africa Recombinant Peptide Sales Market Share by Application in 2020
Figure 69. Egypt Recombinant Peptide Revenue Growth 2016-2021 ($ Millions)
Figure 70. South Africa Recombinant Peptide Revenue Growth 2016-2021 ($ Millions)
Figure 71. Israel Recombinant Peptide Revenue Growth 2016-2021 ($ Millions)
Figure 72. Turkey Recombinant Peptide Revenue Growth 2016-2021 ($ Millions)
Figure 73. GCC Country Recombinant Peptide Revenue Growth 2016-2021 ($ Millions)
Figure 74. Channels of Distribution
Figure 75. Distributors Profiles


★調査レポート[世界の組換えペプチド市場予測 2021年-2026年] (コード:LPI21MY9566)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の組換えペプチド市場予測 2021年-2026年]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆